RemeGen licenses Telitacicept to Vor Biopharma for $4.23 billion
RemeGen licenses Telitacicept to Vor Biopharma for $4.23 billion, including upfront payment, warrants, and milestone payments, for global rights excluding Greater China.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.